Gyre Therapeutics (NASDAQ:GYRE) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS

Gyre Therapeutics (NASDAQ:GYRE) released its earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06), FiscalAI reports. Gyre Therapeutics had a negative net margin of 5.44% and a positive return on equity of 3.13%. The company had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $26.49 million.

Gyre Therapeutics Trading Up 4.2%

GYRE traded up $0.27 during trading on Friday, hitting $6.67. 67,603 shares of the company’s stock were exchanged, compared to its average volume of 52,226. Gyre Therapeutics has a 1 year low of $5.44 and a 1 year high of $9.42. The stock has a 50 day moving average price of $6.25 and a 200 day moving average price of $7.07. The firm has a market cap of $743.63 million, a P/E ratio of -74.10 and a beta of 1.92.

Insider Transactions at Gyre Therapeutics

In related news, COO Weiguo Ye sold 12,820 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the completion of the sale, the chief operating officer directly owned 700,000 shares in the company, valued at approximately $4,305,000. This represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 9.50% of the company’s stock.

Institutional Trading of Gyre Therapeutics

Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after purchasing an additional 89,390 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock valued at $1,194,000 after buying an additional 45,772 shares during the last quarter. Millennium Management LLC purchased a new position in Gyre Therapeutics in the 3rd quarter valued at about $267,000. State Street Corp grew its stake in shares of Gyre Therapeutics by 10.7% during the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock valued at $1,428,000 after acquiring an additional 19,472 shares in the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Gyre Therapeutics during the third quarter valued at about $111,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on GYRE shares. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 11th. Finally, Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.00.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.